Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Melina Arazy"'
Autor:
Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin, Tuphan K. Dolai, Dinesh K. Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Z. Badros, Larry D. Anderson, Nizar J. Bahlis, Michele Cavo, Yi Chai, Jacqueline Jeha, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Paul G. Richardson, Sebastian Grosicki
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Abstract Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in t
Externí odkaz:
https://doaj.org/article/20b9da9076424d1f8dc1d21eef7bc3c4
Autor:
Sosana Delimpasi, Maria Victoria Mateos, Holger W. Auner, Maria Gavriatopoulou, Meletios A. Dimopoulos, Hang Quach, Halyna Pylypenko, Roman Hájek, Xavier Leleu, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Reuben Benjamin, Mamta Krishnan Garg, Vadim Doronin, Yair Levy, Philippe Moreau, Yi Chai, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Paul G. Richardson, Sebastian Grosicki
Publikováno v:
American Journal of Hematology. 97
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dce8bc95e08e02fac35d11080bb1d858
https://doi.org/10.1002/ajh.26434
https://doi.org/10.1002/ajh.26434
Autor:
Sosana, Delimpasi, Maria Victoria, Mateos, Holger W, Auner, Maria, Gavriatopoulou, Meletios A, Dimopoulos, Hang, Quach, Halyna, Pylypenko, Roman, Hájek, Xavier, Leleu, Tuphan Kanti, Dolai, Dinesh Kumar, Sinha, Christopher P, Venner, Reuben, Benjamin, Mamta Krishnan, Garg, Vadim, Doronin, Yair, Levy, Philippe, Moreau, Yi, Chai, Melina, Arazy, Jatin, Shah, Sharon, Shacham, Michael G, Kauffman, Paul G, Richardson, Sebastian, Grosicki
Publikováno v:
American journal of hematology. 97(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::543ce5f08391ae02c2ecc8751f19ebf2
https://pubmed.ncbi.nlm.nih.gov/34882831
https://pubmed.ncbi.nlm.nih.gov/34882831
Autor:
Vadim A Doronin, Maryana Simonova, Philippe Moreau, Ludek Pour, Larry D. Anderson, Sosana Delimpasi, Nizar J. Bahlis, Hang Quach, Reuben Benjamin, Christopher P. Venner, Thierry Facon, Jatin P. Shah, Halyna Pylypenko, Mamta Garg, Roman Hájek, Maria Gavriatopoulou, Holger W. Auner, Meletios A. Dimopoulos, Irina Kryachok, Maria V. Mateos, Michele Cavo, Ganna Usenko, Sundar Jagannath, Moshe Yair Levy, Michael Kauffman, Sharon Shacham, Sebastian Grosicki, Xavier Leleu, Ivan Spicka, Melina Arazy, Yi Chai, Dinesh Kumar Sinha, Ashraf Z. Badros, Don A. Stevens, Paul G. Richardson, Tuphan Kanti Dolai
Publikováno v:
Blood. 136:48-50
Introduction Selinexor is a first-in-class, oral, potent selective inhibitor of nuclear export (SINE) which blocks XPO1, forcing the nuclear retention and activation of tumor suppressor proteins, leading to cancer cell apoptosis. Selinexor has demons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92b852e8d6b07ea1304876ee386b0f29
https://doi.org/10.1182/blood-2020-138391
https://doi.org/10.1182/blood-2020-138391
Autor:
Nizar J. Bahlis, Holger W. Auner, Jatin P. Shah, Halyna Pylypenko, Maria V. Mateos, Michele Cavo, Dinesh Kumar Sinha, Ashraf Z. Badros, Mamta Garg, Sebastian Grosicki, Sundar Jagannath, Xavier Leleu, Larry D. Anderson, Meletios A. Dimopoulos, Melina Arazy, Moshe Yair Levy, Michael Kauffman, Don A. Stevens, Ganna Usenko, Irina Kryachok, Yi Chai, Maryana Simonova, Sharon Shacham, Philippe Moreau, Paul G. Richardson, Ludek Pour, Maria Gavriatopoulou, Ivan Spicka, Christopher P. Venner, Thierry Facon, Reuben Benjamin, Vadim A Doronin, Tuphan Kanti Dolai, Sosana Delimpasi, Hang Quach
Publikováno v:
Blood. 136:50-52
Introduction Selinexor is a first-in-class, oral, potent selective inhibitor of nuclear export (SINE) which blocks XPO1, forcing the nuclear retention and activation of tumor suppressor proteins, leading to cancer cell apoptosis. Selinexor has demons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8d1adfc81e4eedd768bc75b4f05040e
https://doi.org/10.1182/blood-2020-137574
https://doi.org/10.1182/blood-2020-137574
Autor:
Ashraf Badros, Nizar J. Bahlis, Roman Hájek, Larry D. Anderson, Vadim A Doronin, Meletios A. Dimopoulos, Jacqueline Jeha, Halyna Pylypenko, Jatin P. Shah, Reuben Benjamin, Sebastian Grosicki, Maria Gavriatopoulou, Dinesh Kumar Sinha, Xavier Leleu, Thierry Facon, Tuphan Kanti Dolai, Michele Cavo, Don A. Stevens, Moshe Yair Levy, Iryna Kriachok, Sundar Jagannath, L. Pour, Paul G. Richardson, Holger W. Auner, Maria V. Mateos, Sharon Shacham, Sosana Delimpasi, Hang Quach, Yi Chai, Mamta Garg, Michael Kauffman, Ivan Spicka, Maryana Simonova, Philippe Moreau, Christopher P. Venner, Ganna Usenko, Melina Arazy
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf7cc61cc2d359ff206c62213e34e08
http://hdl.handle.net/10044/1/89189
http://hdl.handle.net/10044/1/89189
Autor:
P. Moreau, Maria Gavriatopoulou, Reuben Benjamin, Tuphan Kanti Dolai, Moshe Yair Levy, Vadim A Doronin, Paul G. Richardson, Hang Quach, Maryana Simonova, Ludek Pour, Don A. Stevens, Halyna Pylypenko, Thierry Facon, Xavier Leleu, Melina Arazy, Christopher P. Venner, Larry D. Anderson, Ashraf Z. Badros, Dinesh Kumar Sinha, Nizar J. Bahlis, Maria-Victoria Mateos, Jatin P. Shah, Sebastian Grosicki, Michele Cavo, Ganna Usenko, Yi Chai, Ivan Spicka, Sundar Jagannath, Roman Hájek, Meletios A. Dimopoulos, Michael Kauffman, Iryna Kriachok, Mamta Garg, Sharon Shacham, Holger W. Auner, Sosana Delimpasi
Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98a9cd6d43172e2122cda2b0568bd327
https://hdl.handle.net/11585/865006
https://hdl.handle.net/11585/865006
Autor:
Hua Chang, Nizar J. Bahlis, Jatin P. Shah, Yi Chai, Shambavi Richard, Sosana Delimpasi, Ganna Usenko, Halyna Pylypenko, Meletios A. Dimopoulos, Holger W. Auner, Don A. Stevens, Ajai Chari, Reuben Benjamin, Melina Arazy, Moshe Yair Levy, Tuphan Kanti Dolai, Ivan Spicka, Hang Quach, Larry D. Anderson, Paul G. Richardson, Xavier Leleu, Maria-Victoria Mateos, Ashraf Z. Badros, Sharon Shacham, Iryna Kriachok, Thierry Facon, Roman Hájek, Sebastian Grosicki, Maryana Simonova, Ludek Pour, Yosef Landesman, Christopher P. Venner, Mamta Garg, Michael Kauffman, Dinesh Kumar Sinha, P. Moreau, Michele Cavo, Sundar Jagannath
Publikováno v:
American Journal of Hematology
In the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1–3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30983d9174caa7eac69167b8271b4ec6
https://hdl.handle.net/11585/865100
https://hdl.handle.net/11585/865100
Autor:
Vesselina Goranova-Marinova, Eirini Katodritou, Mamta Garg, Michael G. Kauffman, Paul G. Richardson, Lingling Li, Monica Galli, Sosana Delimpasi, Sebastian Grosicki, Jelena Bila, Galina Salogub, Dinesh Kumar Sinha, Holger W. Auner, Larry D. Anderson, Sybiryna Korenkova, Don A. Stevens, Melina Arazy, Reuben Benjamin, Supratik Basu, Jacqueline Jeha, Moshe Yair Levy, Artur Jurczyszyn, Nizar J. Bahlis, Jean Richard Saint-Martin, Jatin P. Shah, Hang Quach, Anna M. Liberati, Tuphan Kanti Dolai, Iryrna Kriachok, Roman Hájek, Anita A. Joshi, Darrell White, Michele Cavo, Sundar Jagannath, Meletios A. Dimopoulos, Xavier Leleu, Hanna Oliynyk, Pawel Robak, Maryana Simonova, Ganna Usenko, Ludek Pour, Maria V. Mateos, Ivan Spicka, Moshe E. Gatt, Atanas Radinoff, Craig T. Wallington-Beddoe, Jeevan Kumar, Vishnuvardhan Peddagali, Halyna Pylypenko, Thierry Facon, Christopher P. Venner, Donna E. Reece, Sharon Shacham, Maria Gavriatopoulou, Yi Chai, Mercedes Gironella, Vadim A Doronin, P. Moreau
Publikováno v:
Lancet (London, England). 396(10262)
Summary Background Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor with bortezomib (a proteasome inhibitor) and dexamethasone ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64360017cbcc0f8fe4ee44615eeefcf
https://pubmed.ncbi.nlm.nih.gov/33933202
https://pubmed.ncbi.nlm.nih.gov/33933202
Autor:
Merav Leiba, Wanda Knopinska Posluszny, Miguel Canales, Seung Tae Lee, Kimberly Ingalls, Sharon Shacham, Don A. Stevens, Xiwen Ma, Antonio Pinto, Melina Arazy, Jatin J. Shah, Merrill Kingman Shum, Tara Arriola, Sudhir Manda, Wojciech Jurczak, Maciej Kaźmierczak, Kai Li, Habte A. Yimer, Grzegorz S. Nowakowski, Anna Sureda, Michael Kauffman
Publikováno v:
Blood. 138:1420-1420
Introduction: Patients with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) who cannot tolerate or who are not eligible for autologous or chimeric antigen receptor T cell (CAR-T) therapy have limited therapeutic options and suboptimal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf8e80e8cf5de62df7a45f6fcfc62d7c
https://doi.org/10.1182/blood-2021-150025
https://doi.org/10.1182/blood-2021-150025